Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > Diffuus grootcellig B-cel NHL > Biomea Covalent-101

Biomea Covalent-101

COVALENT-101: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 2:25